Dear Doctor, The evolving landscape of oncology continues to present complex clinical decisions in ALK-positive NSCLC and relapsed/refractory ALL, with increasing focus on resistance patterns, CNS disease control, and depth of remission. Therapies such as Lorlatinib and Inotuzumab ozogamicin have introduced new dimensions in treatment sequencing and outcome optimization.
We invite you to share your clinical perspectives through a brief survey.